Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Merck
QuintilesIMS
Chubb
Harvard Business School
Colorcon

Generated: September 19, 2019

DrugPatentWatch Database Preview

Patent: 10,233,248

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,233,248
Title:Treatment of C1013G/CXCR4-associated waldenstroom\'s macroglobulinemia with an anti-CXCR4 antibody
Abstract: The present disclosure provides a method for treating a subject afflicted with Waldenstrm\'s macroglobulinemia (WM) comprising administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that specifically binds to a CXCR4 receptor expressed on the surface of a WM cell. The disclosure also provides a therapeutic regimen for treating a patient afflicted with C1013G/CXCR4-associated WM.
Inventor(s): Ghobrial; Irene M. (Wellesley, MA), Roccaro; Aldo M. (Boston, MA), Cardarelli; Josephine M. (San Carlos, CA), Sacco; Antonio (Boston, MA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:15/034,964
Patent Claims:see list of patent claims

Details for Patent 10,233,248

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26 ➤ Sign Up Bristol-Myers Squibb Company (Princeton, NJ) 2033-11-06 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Mallinckrodt
Deloitte
AstraZeneca
Covington
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.